A neurotechnology company focused on mapping the wiring of the human brain has closed a $27.2 million funding round, adding to a growing body of investment in AI-powered tools for understanding neurological conditions.
According to a report by Pulse 2.0, Omniscient Neurotechnology completed the Series D round to advance its platform, which uses artificial intelligence to generate detailed maps of how different regions of a patient's brain are connected to one another. These maps, sometimes called connectomes, are built from standard MRI data and processed through the company's software to produce individualized pictures of brain circuitry.
The technology is aimed at clinical use. Neurosurgeons and neurologists can use the maps to understand how a specific patient's brain is organized before planning procedures, particularly surgeries that carry a risk of disrupting critical functions like movement or speech. By seeing where connections run in an individual brain rather than relying on population averages, clinicians can potentially make more precise decisions.
Omniscient's platform, known as Quicktome, processes diffusion MRI scans and generates network-level data that goes beyond what a standard imaging read provides. The company has positioned this as a tool that fits into existing clinical workflows without requiring new scanning hardware, which lowers the barrier to adoption in hospital settings.
Brain connectivity mapping has historically been a research tool rather than a clinical one. The challenge has been turning complex, high-dimensional imaging data into something a surgeon or physician can act on quickly. Omniscient has focused on that translation layer, building software that produces outputs formatted for clinical decision-making rather than academic analysis.
The Series D brings the company's total funding to a level that supports broader commercial expansion. Omniscient is headquartered in Sydney, Australia, and has been working to grow its presence in the United States market, where neurosurgical volume and hospital technology budgets are among the largest in the world.
The company did not disclose the names of all investors who participated in the round. The funding is expected to support continued development of the Quicktome platform as well as expansion of the company's clinical and commercial teams.
